---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000742"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:58:37.313285+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evofem signs manufacturing deal to cut PHEXXI cost ~55-60%; extends merger close to Sept 2025 with $1.5M investment

## Summary
- Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.
- No cost to Evofem for tech transfer; Windtree engaged a manufacturer.
- Fifth Amendment extends merger consummation date to Sept 30, 2025.
- Aditxt must invest $1.5M by April 7, 2025 via F-1 preferred or notes.
- Evofem to use best efforts to hold shareholder meeting by Sept 26, 2025.

## SEC filing metadata
- accession: 0001641172-25-000742
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000164117225000742/0001641172-25-000742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000164117225000742/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000742
- JSON: https://secwatch.observer/filing/0001641172-25-000742.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.